Viking Therapeutics, Inc. VKTX

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

We are a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders.

In January 2022, we announced the initiation of a Phase 1 single ascending dose, or SAD, and multiple ascending dose, or MAD, clinical trial of VK2735, a novel dual agonist of the glucagon-like peptide 1, or GLP-1, and glucose-dependent insulinotropic polypeptide, or GIP, receptors. VK2735 is being developed in both oral and subcutaneous formulations for the potential treatment of various metabolic disorders such as obesity.

In March 2023, we announced the completion of the Phase 1 trial. The study was a randomized, double-blind, placebo-controlled, SAD and MAD study in healthy adults. The primary objectives of the study included evaluation of the safety and tolerability of single and multiple doses of VK2735 delivered subcutaneously and the identification of VK2735 doses suitable for further clinical development. Study investigators also evaluated the pharmacokinetics of single and multiple doses of VK2735. Based upon the results from this Phase 1 study, in September 2023, we initiated the VENTURE study, a Phase 2 clinical trial of VK2735 in patients with obesity.

Last close 24.21 2026-10-26
Market cap $2.82B 2026-06-30 share count
52-week range 24.00 - 43.15

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-3.19

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $0$0$0$0$0$0$0$0$0$0
R&D $345.0M$101.6M$63.8M$54.2M$45.0M$31.9M$23.6M$19.0M$13.7M$9.0M
SG&A $48.4M$49.3M$37.0M$16.1M$10.7M$10.7M$9.1M$7.1M$5.3M$4.8M
Total operating expenses $393.3M$150.9M$100.8M$70.4M$55.7M$42.7M$32.7M$26.2M$19.1M$13.8M
Operating income -$393.3M-$150.9M-$100.8M-$70.4M-$55.7M-$42.7M-$32.7M-$26.2M-$19.1M-$13.8M
Pre-tax income -$359.6M-$110.0M-$85.9M-$68.9M-$55.0M-$39.5M-$25.8M-$22.1M-$20.6M-$14.7M
Income tax $1.0K$1.0K$1.0K$1.0K$2.0K$0$0$0$0$0
Net income -$359.6M-$110.0M-$85.9M-$68.9M-$55.0M-$39.5M-$25.8M-$22.1M-$20.6M-$14.7M
EPS, basic -3.19-1.01-0.91-0.90-0.71—————
EPS, diluted -3.19-1.01-0.91-0.90-0.71-0.54-0.36-0.38-0.79-0.90
Shares, diluted (wtd. avg.) 112.7M109.0M94.3M76.8M77.2M—————

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $165.8M$26.7M$55.5M$36.6M$26.4M$29.1M$8.4M$24.8M$9.0M$3.1M
Short-term investments $539.9M$875.9M$306.6M$118.9M$175.7M$219.3M$267.3M$276.7M$11.6M—
Total current assets $715.6M$907.2M$367.2M$167.0M$210.5M$256.1M$283.5M$302.1M$21.9M$14.0M
Total assets $715.7M$908.3M$368.5M$168.5M$210.7M$256.5M$284.3M$302.3M$22.1M$14.5M
Accounts payable $53.3M$9.8M$7.5M$8.5M$1.4M$4.0M$2.4M$959.0K$1.5M$1.2M
Total current liabilities $76.7M$27.4M$19.1M$21.9M$8.8M$12.1M$6.8M$4.5M$8.7M$6.5M
Total liabilities $76.7M$28.0M$20.1M$23.2M$8.8M$12.2M$7.1M$4.6M$8.7M$6.5M
Retained earnings -$847.5M-$487.9M-$377.9M-$292.0M-$223.2M-$168.2M-$128.7M-$102.9M-$80.9M-$60.3M
Total equity $639.1M$880.3M$348.4M$145.3M$201.9M$244.3M$277.1M$297.8M$13.5M$8.0M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$278.7M-$87.8M-$73.4M-$48.4M-$47.6M-$21.8M-$24.8M-$18.8M-$14.8M-$11.1M
Stock-based compensation $40.8M$29.7M$16.8M$8.7M$6.1M$5.8M$3.7M$2.6M$1.5M$1.8M
Investing cash flow $341.4M-$553.4M-$179.1M$54.8M$38.0M$41.6M$7.5M-$265.7M-$1.7M$3.0M
Financing cash flow $76.4M$612.5M$271.4M$4.2M$6.9M$950.0K$887.0K$300.3M$22.4M$10.3M
Buybacks ———$6.8M—————$229

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-046876.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -400M -300M -200M -100M 0 Revenue, FY2016: 0 Net income, FY2016: -14.7M Revenue, FY2017: 0 Net income, FY2017: -20.6M Revenue, FY2018: 0 Net income, FY2018: -22.1M Revenue, FY2019: 0 Net income, FY2019: -25.8M Revenue, FY2020: 0 Net income, FY2020: -39.5M Revenue, FY2021: 0 Net income, FY2021: -55M Revenue, FY2022: 0 Net income, FY2022: -68.9M Revenue, FY2023: 0 Net income, FY2023: -85.9M Revenue, FY2024: 0 Net income, FY2024: -110M Revenue, FY2025: 0 Net income, FY2025: -359.6M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Gross profit — — — — — — — — — —
Net income -$14.7M -$20.6M -$22.1M -$25.8M -$39.5M -$55.0M -$68.9M -$85.9M -$110.0M -$359.6M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Results announced Item 2.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Results announced Item 2.02
  • Shareholder vote Item 5.07
  • Results announced Item 2.02
  • Auditor changed The company changed auditors. Sometimes routine; historically one of the more reliable warnings that something is wrong. Item 4.01
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.7x 44.7%
JNJ JOHNSON & JOHNSON $641.76B 24.1x 6.0%
ABBV AbbVie Inc. $506.70B 121.5x 8.6%
MRK Merck & Co., Inc. $346.91B 19.3x 1.3%
ABT ABBOTT LABORATORIES $182.68B 28.2x 5.7%
PFE PFIZER INC $169.79B 21.9x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $131.16B 33.8x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.85B 17.8x -0.2%